Biomotion Sciences Ordinary Shares (SLXN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomotion Sciences Ordinary Shares (SLXN) has a cash flow conversion efficiency ratio of -1.159x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.02 Million) by net assets ($2.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biomotion Sciences Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Biomotion Sciences Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Biomotion Sciences Ordinary Shares carry for a breakdown of total debt and financial obligations.
Biomotion Sciences Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomotion Sciences Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AEW UK REIT Plc
LSE:AEWU
|
0.029x |
|
Nexus Gold Corp
V:NXS
|
0.605x |
|
Renold
LSE:RNO
|
0.166x |
|
Jura Energy Corporation
V:JEC
|
-0.256x |
|
Aclarion Inc
NASDAQ:ACON
|
-0.093x |
|
Jadestone Energy Inc
LSE:JSE
|
-0.014x |
|
Ion Energy Ltd
V:ION
|
-0.208x |
|
TCI Finance Limited
NSE:TCIFINANCE
|
0.009x |
Annual Cash Flow Conversion Efficiency for Biomotion Sciences Ordinary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Biomotion Sciences Ordinary Shares from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Biomotion Sciences Ordinary Shares.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.60 Million | $-10.82 Million | -4.156x | -297.47% |
| 2024-12-31 | $-3.99 Million | $-8.40 Million | 2.105x | +460.29% |
| 2023-12-31 | $-12.06 Million | $-4.53 Million | 0.376x | -20.26% |
| 2022-12-31 | $-7.08 Million | $-3.33 Million | 0.471x | +3946.78% |
| 2021-12-31 | $114.91 Million | $-1.41 Million | -0.012x | -102.78% |
| 2020-12-31 | $-169.99K | $-75.00K | 0.441x | -- |
About Biomotion Sciences Ordinary Shares
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more